Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence
Objective: To demonstrate the types of clinical recommendations a pharmacogenomics pharmacist may make to medical clinicians with regard to medication management to improve therapeutic outcomes based on varied levels of medical literature evidence. Summary: This case demonstrates how a common ty...
Main Authors: | Michael J. Schuh, Sheena Crosby |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Minnesota Libraries Publishing
2020-05-01
|
Series: | INNOVATIONS in Pharmacy |
Subjects: | |
Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/3228 |
Similar Items
-
Exome-Wide Analysis of the DiscovEHR Cohort Reveals Novel Candidate Pharmacogenomic Variants for Clinical Pharmacogenomics
by: Maria-Theodora Pandi, et al.
Published: (2020-05-01) -
Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use
by: Vid Mlakar, et al.
Published: (2016-09-01) -
Editorial: Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation
by: Masahiro Hiratsuka, et al.
Published: (2021-08-01) -
Actionable Pharmacogenetic Variation in the Slovenian Genomic Database
by: Keli Hočevar, et al.
Published: (2019-03-01) -
Additional Utility of Pharmacogenomics (PGx) Panel Testing in a CYP2D6 Normal Metabolizer with a History of Breast Cancer
by: Michael Schuh
Published: (2019-07-01)